Form 4: Director Michael Gilman Increases Stake in Scholar Rock

Director Michael Gilman acquired 6,839 restricted stock units and 4,310 stock options in Scholar Rock Holding Corp.

Summary

• Director Michael Gilman received an equity grant consisting of 6,839 restricted stock units (RSUs) and 4,310 stock options.
• The RSUs are valued at $0.00 at grant and vest on the earlier of June 15, 2027, or the next Annual Meeting.
• The stock options have an exercise price of $45.33 and expire on June 4, 2036.
• Following these transactions, the director's total beneficial ownership stands at 62,055 shares.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral administrative filing reflecting standard director compensation practices.

Positives

• Alignment of director interests with shareholders through equity-based compensation.
• Retention of key leadership through standard vesting schedules.

Negatives

• Dilutive impact of new equity grants, though standard for corporate governance.

Risks

• Market volatility affecting the value of the granted options.
• Dependence on continued service for the vesting of equity awards.

Future Outlook

The filing does not provide forward-looking financial guidance, focusing solely on director compensation.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard practice in the biotechnology sector to ensure long-term alignment with corporate milestones and shareholder value.

Comparison to Industry Standards

• The grant of RSUs and options is consistent with standard compensation packages for non-employee directors in mid-cap biotech firms.
• Vesting schedules tied to annual meetings are common practice to ensure board continuity.

Corporate Governance

Stakeholder Impact

• Shareholders benefit from director alignment with long-term company performance.

Next Steps

• Vesting of RSUs on June 15, 2027 or the next Annual Meeting.
• Vesting of stock options on the first anniversary of the grant or the next Annual Meeting.

Key Dates

Keywords

Scholar Rock, SRRK, Form 4, Insider Trading, Equity Compensation, Biotech